AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Rakuten Securities Inc.

by · The Cerbat Gem

Rakuten Securities Inc. reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 30.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 890 shares of the company’s stock after selling 391 shares during the period. Rakuten Securities Inc.’s holdings in AstraZeneca were worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. lifted its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new stake in AstraZeneca during the 2nd quarter worth about $26,000. Capital Performance Advisors LLP acquired a new stake in AstraZeneca during the 3rd quarter worth about $28,000. Pathway Financial Advisers LLC purchased a new stake in AstraZeneca during the 1st quarter valued at about $29,000. Finally, RFP Financial Group LLC increased its holdings in shares of AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

Check Out Our Latest Stock Report on AZN

AstraZeneca Price Performance

NASDAQ:AZN opened at $65.19 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company has a 50 day moving average price of $76.61 and a 200-day moving average price of $78.54. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market cap of $202.13 billion, a price-to-earnings ratio of 31.49, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).